DeepMed Research

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

BGB-A1217

Generic Name: BGB-A1217

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer

Phase 2

Withdrawn

Posted: 2023/04/12

Sponsor:Novartis Pharmaceuti...

Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC.

Phase 3

Withdrawn

Posted: 2023/03/30

Sponsor:Novartis Pharmaceuti...

Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer

Phase 2

Completed

Posted: 2022/10/13

Sponsor:BeiGene

Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB A1217) in Combination With Tislelizumab (BGB A317) or Rituximab

Phase 1

Completed

Posted: 2022/03/04

Sponsor:BeiGene

Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer

Phase 2

Completed

Posted: 2021/08/20

Sponsor:BeiGene

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

BeiGene Discontinues TIGIT Inhibitor Ociperlimab After Phase III Trial Failure Prediction

2 months ago

BeiGene has halted development of its TIGIT inhibitor ociperlimab after predictive analyses indicated the Phase III clinical trial was unlikely to meet its primary endpoints.

BeiGene Discontinues Ociperlimab Development After Failed Phase III Lung Cancer Trial

2 months ago

BeiGene has terminated development of its anti-TIGIT antibody ociperlimab following a futility analysis showing the drug was unlikely to meet overall survival endpoints in non-small cell lung cancer.

Roche's Tiragolumab Combination Shows Inferior Outcomes in Advanced NSCLC Trial

3 months ago

Roche's phase 2/3 SKYSCRAPER-06 trial reveals tiragolumab plus Tecentriq and chemotherapy performed worse than Keytruda-chemo combination in first-line advanced non-squamous NSCLC treatment.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy